It’s a chance to get all of your questions about Sonia 2 answered from the lead doctor of the Liverpool trial centre.
Sonia 2 is our second clinical trial, lasting four years, which will test the effectiveness of nitisinone as a treatment for AKU. Nitisinone is thought to be effective in treating AKU, because it works by stopping the production of homogentisic acid (HGA) – a toxic acid which causes the damage in AKU. It’s currently licensed for use in another rare disease, but it is yet to be approved for use in patients with AKU.
If the trial is successful we will apply to get the drug licensed, hopefully giving patients all over the world access to the very first treatment for AKU. Professor Ranganath, from the Royal Liverpool University Hospital, is the Principal Investigator of the trial and will be hosting the webinar.
He will give a short presentation with information on nitisinone and Sonia 2, outlining what patients participating in the trial can expect. Following Dr Ranganath’s presentation will be a question and answer session, where he will discuss any concerns or questions you may have with you.
It will be held on the 24th of July at 3:30pm (BST) and it’s expected to last about 45 minutes. Anyone interested in the trial is welcome to attend, but please do note the webinar will be in English. A recording of the webinar will be available online afterwards for those who cannot attend.
If you would like to attend, please email Hana Ayoob, our Clinical Trials Coordinator, on [email protected], including any questions you have for Dr Ranganath to answer during the webinar. Hana will then email you instructions on how to join the webinar with RareConnect.
This webinar will focus mainly on Sonia 2. If you have any other general questions, such as about nitisinone, see if they were answered during our previous clinical trials webinar here.
For more information ahead of the webinar, and to have a read of Hana’s updates on the DevelopAKUre trial blog, please visit our clinical trials website: www.developakure.eu.